537705-05-8

Basic information

• Product Name: 6-iodo-N-(3-Methyl-4-((6-Methylpyridin-3-yl)oxy)phenyl)quinazolin-4-aMine
• Synonyms: 6-iodo-N-(3-Methyl-4-((6-Methylpyridin-3-yl)oxy)phenyl)quinazolin-4-aMine;6-IODO-N-(3-METHYL-4-((6-METHYLPYRIDIN-3-YL)OXY)PHENYL)QUINAZOLIN-4-AMINE(WXG00470)
• CAS NO: 537705-05-8
• Molecular Formula: C₂₁H₁₇IN₄O
• Molecular Weight: 468.29035
• EINECS: -0
• Mol File: 537705-05-8.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 553.8±50.0 °C(Predicted)
• Appearance: /
• Density: 1.590±0.06 g/cm3(Predicted)
• PKA: 5.40±0.50(Predicted)
• CAS DataBase Reference: 6-iodo-N-(3-Methyl-4-((6-Methylpyridin-3-yl)oxy)phenyl)quinazolin-4-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-iodo-N-(3-Methyl-4-((6-Methylpyridin-3-yl)oxy)phenyl)quinazolin-4-aMine(537705-05-8)
• EPA Substance Registry System: 6-iodo-N-(3-Methyl-4-((6-Methylpyridin-3-yl)oxy)phenyl)quinazolin-4-aMine(537705-05-8)

Safety Data

• Hazardous Substances Data: 537705-05-8(Hazardous Substances Data)

Upstream product

• 537705-06-9 3-(2-methyl-4-aminophenoxy)-6-methylpyridine 
• 16064-08-7 6-iodoquinazolin-4(3H)-one 
• 5326-47-6 2-amino-5-iodobenzoic acid 
• 13290-74-9 1-chloro-2-methyl-4-nitrobenzene 
• 16064-08-7 6-iodo-4-hydroxyquinazoline 
• 697299-78-8 2-methyl-5-(2-methyl-4-nitrophenoxy)pyridine 
• 1121-78-4 5-Hydroxy-2-methylpyridine 
• 98556-31-1 4-chloro-6-iodoquinazoline 

Downstream Products

• 537705-08-1 CP-724714 
• 383432-38-0 (E)-2-methoxy-N-(3-{4-[3-methyl-4-(6-methylpyridin-3-yloxy)phenylamino]quinazolin-6-yl}allyl)acetamide 
• 1260402-01-4 N-(4-(6-methylpyridin-3-yloxy)-3-methylphenyl)-6-(5-((4-methyl-1,4-azaphosphinan-1-yl)methyl)furan-2-yl)quinazolin-4-amine 
• 1260402-39-8 5-(4-(4-(6-methylpyridin-3-yloxy)-3-methylphenylamino)quinazolin-6-yl)furan-2-carbaldehyde 

Relevant articles and documents

Compounds capable of inhibiting ErbB/HDAC and preparation method thereof, and pharmaceutical composition comprising compounds and application thereof

The invention relates to compounds capable of inhibiting ErbB/HDAC and a preparation method thereof, and a pharmaceutical composition comprising the compounds and application thereof. The compounds are disclosed as Formula 1. The compounds or pharmaceutically acceptable salts, solvates, esters, acids, metabolites or prodrugs thereof, or the pharmaceutical composition comprising the compounds can be used for preparing ErbB kinases and HDAC activity inhibitors and also preparing ErbB-kinase/HDAC-activated mediated disease curatives.

[...] tyrosine kinase inhibitor and its preparation and application

The invention discloses a [...] tyrosine kinase inhibitor and its preparation and application, the tyrosine kinase inhibitor is [...] general formula (I) a compound represented by the formula, its various optical isomer or its pharmaceutically acceptable salt; in accordance with the preparation process of the preparation method of the conventional compounds. The [...] tyrosine kinase inhibitor on tyrosine kinase have a strong inhibiting activity, has excellent pharmacokin nature, the cardiovascular system has very good safety and can significantly inhibit the growth of tumors, can be used in the preparation of the treatment of tyrosine kinase-related disease.

PHOSPHORUS CONTAINING QUINAZOLINE COMPOUNDS AND METHODS OF USE

Disclosed are novel quinazoline derivatives containing phosphorus substitutions and methods for the treatment of hyperproliferative diseases (e.g. cancer) using the compounds. These compounds are type I receptor protein kinase inhibitors useful in treating disorders related to abnormal protein kinase activities such as cancer and inflammation in mammals. Also disclosed are pharmaceutical compositions containing the compounds, methods for the preparation of the compounds and their pharmaceutically acceptable salts.